RESEARCH PAPER
Additive suppression of tonic-clonic seizures in mice receiving the combination of carbamazepine, phenobarbital and valproate
1
Department of Pathophysiology, Medical University of Lublin, Poland
2
Department of Toxicology and Food Safety, Institute of Rural Health, Lublin, Poland
3
Institute of Environmental Protection – National Research Institute in Warsaw, Poland
4
Isobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland
Corresponding author
Jarogniew J. Łuszczki
Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8B, 20-090, Lublin, Poland
Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8B, 20-090, Lublin, Poland
J Pre Clin Clin Res. 2019;13(2):72-75
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Introduction. Polytherapy with three antiepileptic drugs (AEDs) is used in patients who have seizure episodes classified by physicians and neurologists as refractory or drug-resistant. Although doctors can prescribe these patients 25 various AEDs, no algorithms are available which allow them to choose the most efficacious combinations of AED.
Objective:
The aim of this study was to isobolographically classify interaction among three classical AEDs (carbamazepine, phenobarbital and valproate), applied in the fixed-ratio combination of 1:1:1, in the maximal electroshock-induced seizures in mice.
Material and methods:
The anti-seizure activity of the mixture of carbamazepine, phenobarbital and valproate (in the fixed-ratio of 1:1:1) was determined in maximal electroshock-induced seizures – an experimental model of tonic-clonic seizures in mice using type I isobolographic analysis.
Results:
The mixture of carbamazepine, phenobarbital and valproate (in the fixed-ratio of 1:1:1) produced additive interaction in the maximal electroshock-induced seizure model in mice. The experimentally-derived median effective dose (ED50 exp value) for the mixture was 94.35 mg/kg, whereas the theoretically additive median effective dose (ED50 add value) amounted to 116.77 mg/kg.
Conclusions:
Although the combination of carbamazepine, phenobarbital and valproate exerted additivity in the mouse maximal electroshock-induced seizure model, it could be recommended for the treatment of patients, if the results of this study would be directly transposed to clinical settings.
Introduction. Polytherapy with three antiepileptic drugs (AEDs) is used in patients who have seizure episodes classified by physicians and neurologists as refractory or drug-resistant. Although doctors can prescribe these patients 25 various AEDs, no algorithms are available which allow them to choose the most efficacious combinations of AED.
Objective:
The aim of this study was to isobolographically classify interaction among three classical AEDs (carbamazepine, phenobarbital and valproate), applied in the fixed-ratio combination of 1:1:1, in the maximal electroshock-induced seizures in mice.
Material and methods:
The anti-seizure activity of the mixture of carbamazepine, phenobarbital and valproate (in the fixed-ratio of 1:1:1) was determined in maximal electroshock-induced seizures – an experimental model of tonic-clonic seizures in mice using type I isobolographic analysis.
Results:
The mixture of carbamazepine, phenobarbital and valproate (in the fixed-ratio of 1:1:1) produced additive interaction in the maximal electroshock-induced seizure model in mice. The experimentally-derived median effective dose (ED50 exp value) for the mixture was 94.35 mg/kg, whereas the theoretically additive median effective dose (ED50 add value) amounted to 116.77 mg/kg.
Conclusions:
Although the combination of carbamazepine, phenobarbital and valproate exerted additivity in the mouse maximal electroshock-induced seizure model, it could be recommended for the treatment of patients, if the results of this study would be directly transposed to clinical settings.
REFERENCES (31)
1.
Brodie MJ. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016;16:82.
2.
Brodie MJ, Sills GJ. Combining antiepileptic drugs--rational polytherapy? Seizure. 2011;20:369–375.
3.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548–1554.
4.
Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11:349–351.
5.
Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations--have newer agents altered clinical outcomes? Epilepsy Res. 2012;98:194–198.
6.
Matsumura N, Nakaki T. Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect. Eur J Pharmacol. 2014;741:237–246.
7.
Załuska K, Kondrat-Wróbel MW, Panasiuk-Poterek AN, Marzęda P, Walczak A, Wróblewska-Łuczka P, et al. Synergy among oxcarbazepine, pregabalin and topiramate in the mouse maximal electroshockinduced seizure test – an isobolographic analysis. J Pre-Clin Clin Res. 2018;12:111–116.
8.
Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41:1364–1374.
9.
Blaszczyk B, Miziak B, Czuczwar P, Wierzchowska-Cioch E, Pluta R, Czuczwar SJ. A viewpoint on rational and irrational fixed-drug combinations. Exp Rev Clin Pharmacol. 2018:1–11.
10.
Kondrat-Wróbel MW, Załuska K, Walczak A, Panasiuk-Poterek AN, Gut-Lepiech A, Wróblewska-Łuczka P, et al. Antagonistic interaction of lacosamide with carbamazepine and valproate in the mouse tonicclonic seizure model. Health Probl Civil. 2019;13:92–98.
11.
Kondrat-Wrobel MW, Luszczki JJ. Additive interaction for three-drug combination of carbamazepine, lacosamide and lamotrigine against maximal electroshock-induced seizures – a type I isobolographic analysis. Eur J Clin Exp Med. 2017;15:303–309.
12.
Kondrat-Wrobel MW, Luszczki JJ. Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model – an isobolographic analysis. Health Probl Civil. 2016;10:55–61.
13.
Kondrat-Wrobel MW, Luszczki JJ. Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model. Adv Clin Exp Med. 2018;27:881–886.
14.
Luszczki JJ. Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2016;97:259–264.
15.
Luszczki JJ, Mazurkiewicz LP, Wroblewska-Luczka P, Wlaz A, Ossowska G, Szpringer M, et al. Combination of phenobarbital with phenytoin and pregabalin produces synergy in the mouse tonic-clonic seizure model: An isobolographic analysis. Epilepsy Res. 2018;145:116–122.
16.
Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl. 1995;162:31–34.
17.
Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:105–114.
18.
Luszczki JJ, Zagaja M, Miziak B, Kondrat-Wrobel MW, Zaluska K, Wroblewska-Luczka P, et al. Beneficial combination of lacosamide with retigabine in experimental animals: an isobolographic analysis. Pharmacology. 2018;101:22–28.
19.
Zolkowska D, Zagaja M, Miziak B, Kondrat-Wrobel MW, Zaluska K, Florek-Luszczki M, et al. Isobolographic assessment of interactions between retigabine and phenytoin in the mouse maximal electroshockinduced seizure model and chimney test. Health Probl Civil. 2016;10:54– 59.
20.
National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance. The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care: pharmacological update of clinical guideline. London: Royal College of Physicians (UK); National Clinical Guideline Centre; 2012.
21.
Litchfield JT, Jr., Wilcoxon F. A simplified method of evaluating doseeffect experiments. J Pharmacol Exp Ther. 1949;96:99–113.
22.
Luszczki JJ. Interactions between pregabalin and phenobarbital in the mouse maximal electroshock-induced seizure model: an isobolographic analysis. J Pre-Clin Clin Res. 2009;3:103–109.
23.
Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model. Epilepsia. 2005;46:344–355.
24.
Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis. Epilepsia. 2006;47:1841–1854.
25.
Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:169–181.
26.
Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285–290.
27.
Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012;342:2–8.
28.
Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995;105:161–179.
29.
Tallarida RJ. Drug synergism and dose-effect data analysis. New York: Chapman and Hall/CRC 2000.
30.
Bourgeois BF, Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity. Epilepsia. 1988;29:482–487.
31.
Bourgeois BF. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin Neuropharmacol. 1988;11:348–359.
Share
RELATED ARTICLE
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
